• unlike
  • Cyproterone itself, unlike CPA, was never introduced for medical use and hence is not available as a medication. (wikipedia.org)
  • Due to its progonadotropic effects in males, unlike CPA, cyproterone has been found, in male rodents, to increase testicular weight, increase the total number of type A spermatogonia, increase the total number of Sertoli cells, hyperstimulate the Leydig cells, and to have almost no effect on spermatogenesis. (wikipedia.org)
  • Also unlike CPA, due to its lack of progestogenic and antigonadotropic activity, cyproterone does not suppress ovulation in women. (wikipedia.org)
  • Unlike CPA, cyproterone seems to show some inhibition of 17β-hydroxysteroid dehydrogenase and 5α-reductase in vitro. (wikipedia.org)
  • treatment
  • Cyproterone was studied as a treatment for precocious puberty by Bierich (1970, 1971), but no significant improvement was observed. (wikipedia.org)
  • In women however, who have much lower levels of testosterone and in whom the drug has no progonadotropic activity, 100 to 200 mg/day oral cyproterone was effective in reducing sebum production in all patients as early as 2 to 4 weeks following the start of treatment. (wikipedia.org)